NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
08 nov. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on...
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
03 nov. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program. Quell...
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
20 sept. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
19 mai 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
22 mars 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
02 févr. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...
Chronic Pain Market to Surpass US$ 108,814 Million by 2028, Says Coherent Market Insights (CMI)
17 nov. 2021 08h40 HE
|
CMI
SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic pain market is estimated to be valued at US$ 64,068 million in 2020 and is expected to exhibit a...
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
08 nov. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
03 août 2021 08h00 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
28 juil. 2021 08h30 HE
|
Tryp Therapeutics Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...